ArticleBiomedical chromatography : BMC2025
Development of a Novel Immunoprecipitation Method for Extracting Monoclonal Antibodies From Brain Tissue and Its Application to Assessing In Vivo Brain Penetration in Mouse via Liquid Chromatography-Mass Spectrometry.
Article in Biomedical chromatography : BMC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A novel extraction method was developed to quantify monoclonal antibodies from brain tissue, crucial for pharmacokinetic assessments. We focused on optimizing detergent use for compatibility with liquid chromatography-mass spectrometry analysis. IGEPAL and sodium deoxycholate were selected for their ability to preserve antibody integrity during extraction, with conditions optimized to a 4% concentration. This was most effective for maintaining antibody structure and maximizing recovery. Pharmacokinetic analysis was conducted on the 8D3 monoclonal antibody, known for its brain penetration abilities. Administered at 20 mg/kg, its concentration in the brain was measured using the optimized extraction methods. The 4% SDC method showed superior extraction efficiency, significantly enhancing brain exposure levels with a higher maximum concentration and area under the curve compared to the 4% IGEPAL and detergent-free methods. This highlights the importance of detergent selection in accurate pharmacokinetic measurements. We also addressed potential blood contamination. Specific perfusion conditions effectively removed 98% of blood contaminants, ensuring that pharmacokinetic measurements reflected true monoclonal antibody levels in brain tissue. Overall, this study establishes a robust method for monoclonal antibody extraction from brain tissue, enhancing the analysis of brain-targeted therapies and providing a valuable framework for future studies aiming to measure drug concentrations in brain tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.